Chemical Profiling and Biological Activity of Psydrax dicoccos Gaertn

Molecules. 2023 Oct 15;28(20):7101. doi: 10.3390/molecules28207101.

Abstract

Breast cancer is one of the deadliest diseases in women with a mortality rate of 6.6%. Adverse effects of synthetic drugs have directed research toward safer alternatives such as natural compounds. This study focused on Psydrax dicoccos Gaertn, an evergreen tree abundantly distributed in Tamil Nadu (India) for its possible application against breast cancer cells. P. dicoccos leaf methanol extract, found within a wide range of phytochemicals, demonstrated cytotoxic effects against MCF7 breast cancer cells at IC50 of 34 μg/mL. The extract exhibited good antioxidant activities against DPPH (62%) and ABTS•+ (80%), as well as concentration-dependent (100-800 μg/mL) anti-inflammatory potential of 18-60% compared to standards, ascorbic acid or aspirin, respectively. Moreover, even low extract concentrations (10 μg/mL) inhibited the growth of Escherichia coli (1.9 ± 0.6 mm) and Pseudomonas aeruginosa (2.3 ± 0.7 mm), thus showing high antimicrobial and anti-inflammatory potential. GC-MS and LC-MS analyses identified 31 and 16 components, respectively, of which selected compounds were used to evaluate the interaction between key receptors (AKT-1, COX-2, and HER-2) of breast cancer based on binding energy (ΔG) and inhibition constant (Ki). The results indicate that bioactive compounds from P. dicoccos have potential against breast cancer cells, but further evaluations are needed.

Keywords: GC-MS; LC-MS; Psydrax dicoccos; anti-inflammatory; antioxidant; cancer; cytotoxicity; molecular docking; phytochemistry.

MeSH terms

  • Anti-Infective Agents* / chemistry
  • Anti-Infective Agents* / pharmacology
  • Anti-Inflammatory Agents / pharmacology
  • Antioxidants / chemistry
  • Breast Neoplasms*
  • Female
  • Humans
  • India
  • Phytochemicals / pharmacology
  • Plant Extracts / chemistry

Substances

  • Plant Extracts
  • Anti-Infective Agents
  • Antioxidants
  • Phytochemicals
  • Anti-Inflammatory Agents

Grants and funding

This research received no external funding.